MARKET

BCTXW

BCTXW

Briacell Therapeutics Corp
NASDAQ
0.0089
0.0000
0.00%
Closed 14:15 02/06 EST
OPEN
0.0017
PREV CLOSE
0.0089
HIGH
0.0089
LOW
0.0017
VOLUME
24.01K
TURNOVER
--
52 WEEK HIGH
0.2500
52 WEEK LOW
0.0017
MARKET CAP
--
P/E (TTM)
-0.0002
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BCTXW last week (0126-0130)?
Weekly Report · 5d ago
BriaCell Therapeutics Reports Tumor Regression in Phase 2 Study of Bria-IMT for Metastatic Breast Cancer
Reuters · 01/28 12:30
BRIACELL PATIENTS’ IMAGES SHOW REGRESSION AND RESOLUTION OF METASTASIZED TUMORS AND IMMUNE ACTIVATION
Reuters · 01/28 12:30
BriaCell Reports Extended Survival in Phase 2 Metastatic Breast Cancer Trial
Reuters · 01/27 17:05
BriaCell Highlights Extended >18-47 MONTHS SURVIVAL IN PHASE 2 METASTATIC BREAST CANCER PATIENTS
Reuters · 01/27 12:30
BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients
Barchart · 01/27 06:30
Weekly Report: what happened at BCTXW last week (0119-0123)?
Weekly Report · 01/26 09:00
Weekly Report: what happened at BCTXW last week (0112-0116)?
Weekly Report · 01/19 09:00
More
About BCTXW
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops immunotherapies to transform cancer care. The Company’s lead drug candidate, Bria-IMT, is a cell-based patented immunotherapy that stimulates a patient’s own cancer fighting cells to attack and destroy breast cancer tumors. The Company is advancing its targeted immunotherapy program by prioritizing a Phase II clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor. The Company is focused on conducting a Phase I/IIa clinical trial of Bria-IMT in a combination study with Incyte’s immune PD-1 inhibitor, retifanlimab, in advanced breast cancer. The Company is also developing Bria-OTS, an off-the-shelf personalized approach to whole cell cancer immunotherapy. The Bria-OTS immunotherapy is based on a patient’s HLA-type. Its pipeline also includes Bria-Pros, Bria-Lung, Bria-Mel and sCD80, which are in development to treat various cancers.

Webull offers Briacell Therapeutics Corp stock information, including NASDAQ: BCTXW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCTXW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCTXW stock methods without spending real money on the virtual paper trading platform.